GlassScriptPhysician profile
Sanjeev N Patel
NPI 1194803361
$9,194.15
in general payments reported to CMS, 2019-2025
22 companies · $1,579 in 2025
The $1,579 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,699 · 2020: $859 · 2021: $1,399 · 2022: $668 · 2023: $2,034 · 2024: $956 · 2025: $1,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,568.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,309.76 | 2019-2025 | Watchman Flx, Resonate El Icd Vr, Watchman Access System |
| Medtronic, INC. | $952.07 | 2021-2025 | Symplicity G3, Corevalve Evolut R |
| Amgen INC. | $734.63 | 2021-2025 | Repatha, Repatha |
| Abiomed | $569.82 | 2021-2025 | Impella |
| Edwards Lifesciences Corporation | $555.13 | 2021-2023 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $544.80 | 2019-2025 | Wainua |
| Novo Nordisk INC | $486.53 | 2023-2025 | Wegovy, Ozempic |
| Pfizer INC. | $478.54 | 2019-2023 | |
| Cvrx, INC. | $434.08 | 2019-2023 | Barostim Neo System |
| Medtronic Vascular, INC. | $402.07 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $397.12 | 2019-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.71 | 2019-2024 | Jardiance |
| Abbott Laboratories | $312.42 | 2019-2023 | Dragonfly Opstar |
| Intra-Sana Laboratories | $292.89 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Janssen Pharmaceuticals, INC | $249.98 | 2023-2024 | Xarelto |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $213.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $186.48 | 2019-2025 | |
| Shockwave Medical, INC | $171.30 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Ancora Heart, INC. | $164.00 | 2019 | |
| Bridgebio Pharma, INC. | $121.70 | 2025 | Attruby |
| Dexcom, INC. | $121.54 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $101.25 | 2021-2025 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.